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from the study if they had received anticoagu-
lant therapy or had undergone carotid revascu-
larization. However, differences aside, the lesson 
from TIAregistry.org should not be that we have 
solved the problem of acute recurrent ischemia, 
but rather that we must redouble our efforts to 
treat patients before these early recurrent events 
can occur. In addition, the search for effective 
interventions must continue.
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The author replies: Differences in 90-day 
stroke risks probably reflect differences between 
routine clinical practice in TIA clinics in Europe, 
Asia, and Latin America that included all patients 
with a TIA and clinical trials that purposely se-
lected high-risk patients.1,2 These differences also 
reflect variations in the provision of care through-
out the world because of economic differences.
In the trial by Wang et al.,1 which was per-
formed in China, only half the patients with 
hypertension received a blood-pressure–lowering 
agent and half the patients with diabetes re-
ceived an antidiabetic drug during the follow-up 
period (Table S3 in the Supplementary Appen-
dix, available with the full text of the article by 
Wang et al. at NEJM.org). Risk-factor control was 
probably even worse before the index event than 
after the index event, and this most likely con-
tributed to the very high rate of stroke (11.7%) 
at 90 days.1 In the ticagrelor trial,2 the overall 
5.9% stroke risk at 90 days was partly driven by 
an 11.5% risk among patients from Asia and 
Australia and by only a 5.2% risk among patients 
in North America.
Current available evidence suggests that 
health authorities should develop TIA clinics to 
immediately assess the cause of the TIA and 
start treatment. We agree that there is still room 
for improvement, particularly in acute anti-
thrombotic therapy.
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To the Editor: In his review article, Strum 
(March 17 issue)1 provides data on the overall prev-
alence of colorectal adenomas in the United States 
and risk factors for these lesions. It is well estab-
lished that patients with Streptococcus bovis–group 
infective endocarditis are at high risk for colorec-
tal cancer.2 Although a strong relationship between 
Enterococcus faecalis endocarditis and colorectal 
adenomas is suspected, robust data are lacking.
Of the 150 patients with a diagnosis of en-
terococcal endocarditis in our cohort from 1979 
through 2013, a total of 108 had E. faecalis endo-
carditis of unknown origin. Of these patients, 
58 (54%) underwent colonoscopy at admission. 
A total of 44 patients (76%) received a new diag-
nosis of colonic disease, including colorectal 
adenoma in 20 patients (34%) and colorectal can-
cer in 5 (9%) (1 patient received a diagnosis dur-
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ing the first year of follow-up).3 This prevalence 
is similar to that of colorectal adenoma and 17 
times as high as that of colorectal cancer among 
patients who were screened with the use of colo-
noscopy in a study by Quintero et al.4 Although 
data are lacking to confirm these findings, at-
tention must be paid to the relationship between 
E. faecalis endocarditis and colorectal cancer.
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To the Editor: In his review article on colorec-
tal adenomas, Strum states that stool DNA tests 
were only moderately sensitive for cancer. How-
ever, the observed 92 to 100% detection rates 
have been very high in stool DNA screening stud-
ies (Fig. 1A)1,2 and rival reported detection rates 
in colonoscopy. Moreover, Table 3 of the article 
contained errors; data on cancer detection by 
means of the stool DNA test and the fecal im-
munochemical test (FIT) were reversed, and the 
statistical comparison of rates of lesion detection 
between the stool test and colonoscopy is invalid 
because the latter was the reference standard.
Small adenomas were discussed extensively, 
but most do not progress. Since most high-grade 
dysplasia occurs in polyps that are larger than 2 
cm in diameter,3 detection of these highest-risk 
large polyps has a greater effect on cancer pre-
vention than does detection of smaller polyps. 
The screening sensitivity of the stool DNA test 
increases with the size of the adenoma (Fig. 
1A).1,2 Consequently, at the recommended fre-
quency of every 3 years, the estimated screening-
program sensitivity of the stool DNA test for 
high-grade dysplasia exceeds 90% by the second 
screening round4; this rate compares favorably 
with that of colonoscopy every 10 years. More-
over, the stool DNA test detects most sessile 
serrated polyps that are larger than 1 cm in 
diameter.1,2 These nonhemorrhagic lesions are 
rarely detected by means of FIT (Fig. 1B) and are 
often overlooked on colonoscopy.
Figure 1. Rates of Detection of Colorectal Neoplasia  
by Means of Stool DNA Testing.
Panel A shows rates of detection of colorectal neo‑
plasms by means of the multitarget stool DNA test in 
an Alaska Native population1 and in the general U.S. 
population.2 Panel B shows rates of detection of sessile 
serrated polyps by means of the multitarget stool DNA 
test and the fecal immunochemical test (FIT) in the 
same Alaska Native population.1 The data shown are 
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To the Editor: Strum covers the topic of colorec-
tal adenomas in great detail. However, the im-
portance of genetic syndromes as a cause of 
colorectal adenomas was underemphasized. Al-
though, as stated, a family history of colorectal 
adenomas is associated with an increased risk of 
the disease, uncovering the genetic cause of the 
disease can help clinicians to adjust the screen-
ing pattern according to the mutation status and 
family history and can lead to a more personal-
ized screening plan. In addition, other at-risk 
persons can be identified.
Since APC mutations were associated with 
colorectal adenomas in 1991, mutations in many 
other genes have been strongly associated with 
these tumors. Specific histologic types of polyps 
have been linked to these genes. For example, 
conventional adenomas have been associated with 
monoallelic mutations in POLE, POLD1, and FOCAD, 
and with biallelic mutations in MUTYH, MLH1, 
MSH2, MSH6, PMS2, and NTHL1. Juvenile polyps 
have been linked to SMAD4 and BMPR1A, Peutz–
Jeghers polyps to STK11, hamartomas to PTEN, 
and mixed polyps to GREM1.1-3 Combining the 
patient’s age at the onset of the polyps and their 
pathological subtype with genetic testing and 
family history can help the clinician to most ef-
fectively treat the patient.
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The authors reply: Pericàs et al. point out the 
association between S. bovis and E. faecalis and 
colorectal cancer. Itzkowitz and Ahlquist indi-
cate that most small adenomas do not progress, 
that most high-grade dysplasia occurs in polyps 
that are 20 mm in diameter or larger, and that 
the sensitivity of the stool DNA test increases 
with the size of the adenoma. It is not clear 
whether Itzkowitz and Ahlquist propose to dis-
count the clinical significance of adenomas that 
are smaller than 20 mm in diameter; if so, the 
detection rates with stool DNA screening could 
reach 60 to 80%.
I have several concerns. First, experts in the 
field indicate that discovery and removal of small 
precancerous adenomas that are larger than 5 mm 
in diameter are relevant objectives of screening 
and prevention.1 Second, the most clinically sig-
nificant cutoff value in use for the size of polyps 
is 9 mm in diameter, and this value has addi-
tional relevance in computed tomographic colo-
nography because colonographers do not rou-
tinely recommend removal of all polyps that are 
smaller than 10 mm in diameter.1 Third, increas-
ing sensitivity in detecting adenomas as they in-
crease in size is not unique to the stool DNA test.
Part of the purpose of my article was to high-
light the wide variance in pathological impor-
tance depending on the size of the lesion. Ad-
vanced adenoma status is attributed to 1.1% of 
diminutive polyps and 1.3% of small polyps, 
whereas this status is attributed to 13.2% of 
large polyps. An improved definition of ad-
vanced adenomas might be those that are larger 
than 9 mm in diameter and contain high-grade 
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dysplasia or villous architecture, rather than tu-
bulovillous architecture.
The inadvertent reversal of data on cancer 
detection by the stool DNA test and FIT in Table 3 
of my article notwithstanding, the thrust of the 
message of Table 3 is that stool-based tests for 
advanced adenoma do not fare well as compared 
with colonoscopy; this has been adroitly shown 
to be valid in the studies by Imperiale et al. and 
Quintero et al. (cited as references 5 and 61 in 
my article, respectively). The assumption by Itz-
kowitz and Ahlquist that stool DNA testing 
might reach a sensitivity of 90% by a second 
round of screening at 3 years is an estimated 
outcome that has not been proved. Stool DNA 
testing is an appealing approach to screening, 
but it involves several obstacles,2 including cost-
ineffectiveness, since a positive test requires 
colonoscopy as a second procedure.3,4
Castellsagué and colleagues note mutations 
that are associated with colon-cancer syndromes. 
Although a discussion of genetic syndromes was 
not a goal of my article, these mutations were 
noted in a reference to an article by Stoffel and 
Boland (cited as reference 15 in my article).
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Point-of-Care Warfarin Monitoring in the ROCKET AF Trial
To the Editor: On February 5, 2016, the Euro-
pean Medicines Agency (EMA) released an assess-
ment report on rivaroxaban (Xarelto), in which it 
described Bayer’s comparison of the international 
normalized ratio (INR) values obtained by the 
Alere INRatio Monitor System (formally known 
as the Hemosense INRatio device) and those ob-
tained by a central laboratory on samples col-
lected at weeks 12 and 24 during the ROCKET AF 
trial.1 Although the point-of-care device reported 
lower INR values than those shown by the labo-
ratory results, the error was not influenced by 
either anemia or conditions causing elevated fi-
brinogen levels. Since this finding negates the 
fundamental assumption in the post hoc analysis 
of the ROCKET AF data by Patel et al.,2 how 
should their results be interpreted? Of the 767 
central-laboratory samples with an INR of more 
than 4 at week 12, the point-of-care device re-
ported values of less than 3 for 219 samples 
(29%).1 Although the EMA found insufficient 
evidence to alter the benefit–risk conclusion of 
the original rivaroxaban study, the agency did 
not address several important questions. How 
many warfarin-treated patients had major bleed-
ing as a result of this error in the point-of-care 
device? Did this error result in a change in the 
percentage of time that patients receiving warfa-
rin were in the therapeutic range? Answers to 
these questions could alter the relative benefit–
risk relationship between rivaroxaban and warfa-
rin. They could also diminish the validity of the 
ROCKET AF study.3
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The authors reply: In response to the com-
ments of Powell and to provide further insight, 
we now present the results of additional analyses 
using central-laboratory INR measurements on 
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